|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Iscalimab appears to be a promising blocker of the CD40-CD154 costimulatory pathway with potential use in transplantation and other autoimmune diseases.
|
31647605 |
2020 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Clinical studies of anti-CD40L molecules in autoimmune diseases have met challenges because of thromboembolic events and adverse haemostasis.
|
31648370 |
2020 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Accordingly, CD40 and its ligand, CD40L, have long been considered targets for the treatment of autoimmune diseases.
|
31109957 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond.
|
30552917 |
2019 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
|
31019027 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Currently, several biological products targeting the CD40-CD154 axis have been developed and are undergoing early phase clinical trials with encouraging success in several autoimmune disorders, including autoimmune arthritis.
|
31426619 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The CD40-CD40L costimulatory pathway is critical for T cell activation in autoimmune disease.
|
30811635 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The CD154-CD40 interactions play a critical role in the regulation of immune responses and the maintenance of autoimmunity.
|
29391506 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Clinical development of Hu5c8, a monoclonal antibody against CD40L intended for treatment of autoimmune disorders, was terminated due to unexpected thrombotic complications.
|
29484632 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Single doses up to 120 mg BI 655064 IV and SC were well tolerated and showed a high potential to block the CD40-CD40L pathway, supporting further clinical development of BI 655064 in patients with autoimmune disease.
|
29127458 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The CD40-CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and lupus nephritis.
|
30113724 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Defects in CD40 and CD40L interactions or in downstream signaling molecules, including activation-induced cytidine deaminase, uracyl-DNA-glycosylase, NF-κB and DNA repair enzymes, result in an increased level of serum IgM and a significantly decreased or absent level of IgA, IgG and IgE that is accompanied by severe recurrent infections and autoimmune diseases.
|
29132233 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Soluble form of CD40L has been widely studied as marker of inflammatory and autoimmune diseases.
|
29050818 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Additionally, we observed the amelioration of autoimmunity following the elevation of IgM targeting pp65<sub>428-437.</sub> CONCLUSIONS: Our data suggest that pp65<sub>428-437</sub> may be an autoimmune or lupus-prone B cell epitope and may catalyze further epitope spreading for inducing autoantibodies in lupus-susceptible individuals.
|
28320458 |
2017 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, CD40-CD40L interactions are crucially involved in development of autoimmune disease in a number of animal models.
|
29773027 |
2017 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The inflammatory CD40-CD40L pathway is implicated in various autoimmune diseases, but the activity status of this pathway in various stages of rheumatoid arthritis (RA) progression is unknown.
|
28455435 |
2017 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Despite the fact that CD40-CD40L pathway plays a key role in development of autoimmune diseases, we were not able to detect gene-gene interactions between CD40 and CD40L polymorphisms associated with multiple sclerosis.
|
24912008 |
2014 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Epigenetic deregulation of genes encoded on the X chromosome as reported for CD40L in lupus could explain the female predominance of autoimmune diseases.
|
24117612 |
2014 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our novel demonstration that in vivo biochemical or genetic inhibition of NFATc2 activity in megakaryocyte diminishes platelet CD40L implicates the NFATc2/EGR-1 axis as a key regulatory pathway of inflammatory and immunomodulatory activity in platelets and represents a target for the development of therapeutics for the potential treatment of chronic inflammatory and autoimmune diseases.
|
24106272 |
2013 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This review focuses on the role of CD40-CD40L (CD154) interactions in dendritic cells (DCs) regulation, tolerogenic dendritic cells, role of CD40 in autoimmune disease, allograft rejection and induction of tolerance by down regulation of CD40.
|
22427471 |
2012 |
|
Autoimmune Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These findings suggest a mechanism for the association of 3'-UTR CA-rich response element polymorphisms with CD154 overexpression and the subsequent risk of autoimmune disease.
|
18640985 |
2008 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Identifying components selectively coupling CD40 to each axis could indicate targets for disruption in B cell pathologies underpinned by ectopic and/or hyper-CD154 activity such as neoplasia and some autoimmunities.
|
17709483 |
2007 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
HIGM patients who carry mutations in the CD40-ligand (CD40L) gene expressed by CD4(+) T cells suffer from recurrent infections and often develop autoimmune disorders.
|
17562816 |
2007 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
CD40-CD154 interaction is an important mediator of inflammation and has been implicated in T helper type 1-mediated autoimmune diseases including rheumatoid arthritis (RA).
|
17845713 |
2007 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This has implications for selective targeting of Egr family members to control abnormal expression of CD154 in autoimmune diseases such as systemic lupus erythematosus.
|
16393964 |
2006 |